Evidence map›Paper›PMID 29470826›Full record

ArticleJournal of endocrinological investigation2018

Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor.

M G Castagna, R Forleo, F Maino, N Fralassi, F Barbato, P Palmitesta, T Pilli, M Capezzone, L Brilli, C Ciuoli and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Diagnostic Usefulness ofDiagnostics (Basel, Switzerland) · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M G CastagnaDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy. m.g.castagna@ao-siena.toscana.it.
R ForleoDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
F MainoDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
N FralassiDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
F BarbatoDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
P PalmitestaDepartment of Social, Political and Cognitive Sciences, University of Siena, Siena, Italy.
T PilliDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
M CapezzoneDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
L BrilliDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
C CiuoliDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
S CantaraDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
C FormichiDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
F PaciniDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.

Funding

Italian Ministry of Health RF-2011-02950673
6 · The paper itself

Abstract

purposeAccording to American Thyroid Association (ATA) guideline, papillary thyroid cancer (PTC) with minimal extrathyroidal extension (mETE) is classified at "intermediate risk" of persistent/recurrent disease. However, the impact of mETE per se on patients' outcome is not fully understood. The aim of our study was to evaluate the prognostic significance of mETE in patients with PTC not submitted to therapeutic or prophylactic lymph node dissection, according to tumor size and other prognostic factors. PATIENTS AND

methodsWe retrospectively evaluated a total of 514 PTC patients: 127 (24.7%) had mETE (pT3Nx) and 387 (75.3%) had negative margins (pT1-2Nx). At a median follow-up of 9.1 years, patients were divided in two groups: patients with "good outcome" (no evidence of disease) and patients with "poor outcome" (persistent structural disease or recurrent disease or tumor-related death).

resultsThe rate of patients with "poor outcome" was significantly higher in patients with mETE compared with patients with negative margins (11.8 versus 5.1%; OR 2.4576, 95% CI 1.2178-4.9594, p = 0.01). However, mETE was significantly associated with poor outcome only in patients with tumors larger than 1.5 cm.

conclusionsmETE is an unfavorable prognostic factor in tumors larger than 1.5 cm, suggesting that, in the absence of other unfavorable characteristics, smaller tumors with mETE should be classified and managed as "low risk" tumors.

Indexed as

Disease ManagementAdolescentAdultAgedAged, 80 and overChildFemaleFollow-Up StudiesHumansMiddle AgedPractice Guidelines as TopicRetrospective StudiesRisk FactorsThyroid Cancer, PapillaryThyroidectomyVoluntary Health AgenciesAggressive histologyMicropapillary thyroid cancerMinimal extrathyroidal extensionPTCTumor diameter

Identifiers

PMID29470826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.